logo
logo
Cytek Biosciences, Inc.

Cytek Biosciences, Inc.

NASDAQ•CTKB
CEO: Dr. Wenbin Jiang Ph.D.
セクター: Healthcare
業種: Medical - Devices
上場日: 2021-07-23
Cytek Biosciences, Inc., a cell analysis solutions company, provides cell analysis tools that facilitates scientific advances in biomedical research and clinical applications. It offers aurora and northern lights systems, which are spectrum flow cytometers that delivers cell analysis by utilizing the fluorescence signatures from multiple lasers to distinguish fluorescent tags on single cells; and aurora cell sorter system that leverages full spectrum profiling technology to further broaden potential applications across cell analysis; aurora CS systems; amnis imagestream imaging flow cytometers; guava muse cell analyzers; guava easycyte flow cytometers; and orion reagent cocktail preparation systems. The company also provides reagents and kits, including cFluor reagents that are fluorochrome conjugated antibodies used to identify cells of interest for analysis on its instruments, as well as 25-color immunoprofiling assay that provides turnkey solutions for identifying major human immune subpopulations for TBNK cells, monocytes, dendritic cells, and basophils. In addition, it offers automated micro-sampling system and automated sample loader system, an automated loaders to integrate seamlessly into the aurora and northern lights systems; SpectroFlo software that provides intuitive workflow from quality control to data analysis for aurora and northern lights systems; and customer support tools. The company serves pharmaceutical and biopharma companies, academic research centers, and clinical research organizations. It distributes its products through direct sales force and support organizations in North America, Europe, China, and the Asia-Pacific regions; and through distributors or sales agents in European, Latin American, and the Middle Eastern countries. The company was formerly known as Cytoville, Inc. and changed its name to Cytek Biosciences, Inc. in August 2015. Cytek Biosciences, Inc. was founded in 1992 and is headquartered in Fremont, California.
連絡先情報
47215 Lakeview Boulevard, Fremont, CA, 94538, United States
877-922-9835
cytekbio.com
時価総額
$533.20M
PER (TTM)
-41.5
31.5
配当利回り
--
52週高値
$6.18
52週安値
$2.37
52週レンジ
47%
順位53Top 76.1%
2.8
F-Score
改良版 Piotroski 分析
6年ファンダメンタル
弱い • 2.8 / 9 ポイント
スコアレンジ (0-9)
8-9: 価値が優れている
6-7: 基礎体質が強い
4-5: 全体的に堅調
0-3: パフォーマンスが弱い
データ期間: 2020-2025

財務ダッシュボード

Q3 2025 データ

売上高

$52.29M+1.54%
直近4四半期の推移

EPS

-$0.04-655.56%
直近4四半期の推移

フリーCF

-$4.55M-136.68%
直近4四半期の推移

2025 Q3 決算ハイライト

主なハイライト

Revenue Decreased 3% Total revenue for nine months ended September 30, 2025 was $139.4M, reflecting a 3% decrease versus prior year.
Gross Margin Pressure Nine-month gross margin declined to 51% from 54% due to increased service labor costs and product overhead.
Operating Loss Widened Loss from operations reached $(34.8)M for nine months, significantly wider than the $(23.5)M loss reported last year.
Cash Used in Operations Net cash used in operating activities totaled $(3.9)M for the nine months ended September 30, 2025.

リスク要因

Single Source Supplier Risk Highly reliant on single or sole source suppliers for key components, risking immediate supply transition difficulties.
Internal Control Material Weaknesses Material weaknesses identified in control environment and activities resulted in disclosure controls being ineffective as of September 30, 2025.
Patent Litigation Exposure Ongoing patent infringement lawsuit with Beckman Coulter requires vigorous defense and may result in significant costs.
Market Adoption Uncertainty Future growth depends on increasing adoption of FSP platform by academic and clinical customers globally.

見通し

R&D Investment Focus Plan continued investment in R&D for new products and expanding reagent offerings across global sales territories.
Recurring Revenue Growth Expect recurring reagent and service revenue to increase leverage as the installed base of instruments expands.
Clinical Market Penetration Pursuing regulatory approvals, including 510(k) clearance, to expand platform applications into the US clinical market.
Infrastructure Scaling Anticipate increasing expenses to scale commercial infrastructure, support growth, and introduce new products and services.

同業比較

売上高 (TTM)

Varex Imaging CorporationVREX
$854.40M
+4.1%
Orthofix Medical Inc.OFIX
$818.06M
+4.3%
Avanos Medical, Inc.AVNS
$699.90M
+2.7%

粗利益率 (最新四半期)

Treace Medical Concepts, Inc.TMCI
79.1%
-1.1pp
Organogenesis Holdings Inc.ORGO
76.0%
-0.8pp
OrthoPediatrics Corp.KIDS
73.9%
+0.5pp

主要指標

銘柄コード
時価総額
PER (TTM)
ROE (TTM)
負債比率
BFLY$770.44M-9.6-37.8%7.3%
AVNS$685.14M-1.5-58.2%12.5%
SRDX$614.51M-34.8-15.6%19.2%

長期トレンド

直近4四半期
売上高
純利益
営業キャッシュフロー
4四半期売上高CAGR
-3.1%
横ばい
4四半期純利益CAGR
N/M
収益構造の変化
キャッシュフロー安定性
50%
キャッシュフローに注意が必要

深度リサーチ

次回決算:2026年2月26日
|
EPS:$0.02
|
売上高:-
財務レポート
財務データ
全年度
  • Form 10-Q - Q3 2025

    会計期末: 2025年9月30日|提出日: 2025年11月5日|
    売上高: $52.29M+1.5%
    |
    EPS: $-0.04-655.6%
    予想を下回る
  • Form 10-Q - Q2 2025

    会計期末: 2025年6月30日|提出日: 2025年8月6日|
    売上高: $45.60M-2.2%
    |
    EPS: $-0.04-44.6%
    予想を上回る
  • Form 10-Q - Q1 2025

    会計期末: 2025年3月31日|提出日: 2025年5月8日|
    売上高: $41.46M-7.6%
    |
    EPS: $-0.09+91.1%
    予想を下回る
  • Form 10-K - FY 2024

    会計期末: 2024年12月31日|提出日: 2025年2月28日|
    売上高: $200.45M+3.9%
    |
    EPS: $-0.05+48.8%
    予想を下回る
  • Form 10-Q - Q3 2024

    会計期末: 2024年9月30日|提出日: 2024年11月7日|
    売上高: $51.50M+7.3%
    |
    EPS: $0.01-115.2%
    予想を下回る
  • Form 10-Q - Q2 2024

    会計期末: 2024年6月30日|提出日: 2024年8月6日|
    売上高: $46.62M-6.2%
    |
    EPS: $-0.08+145.8%
    予想を下回る
  • Form 10-Q - Q1 2024

    会計期末: 2024年3月31日|提出日: 2024年5月8日|
    売上高: $44.86M+21.0%
    |
    EPS: $-0.05-6.2%
    予想を下回る
  • Form 10-K - FY 2023

    会計期末: 2023年12月31日|提出日: 2024年3月13日|
    売上高: $193.02M+17.7%
    |
    EPS: $-0.09-567.7%
    予想を下回る